IAVI HIV Vaccine Trials Backed by Gates Foundation CAVD Show First Proof-of-Concept for Broadly Neutralising Antibody Priming
Results from IAVI G001, G002, and G003 clinical trials — supported through the Gates Foundation's $287 million Collaboration for AIDS Vaccine Discovery (CAVD) network — showed that targeted protein vaccines can activate rare germline precursor immune cells for HIV broadly neutralising antibodies. IAVI G003 enrolled participants in South Africa and Rwanda — the first African bNAb-priming trial results — validating the stepwise rational vaccine design approach against a pathogen affecting 38 million people globally.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Grants Pfizer $100 Million for Group B Streptococcus Maternal Vaccine Phase 3 and LMIC Access
Next →
Gates Foundation Commits $50 Million to Vir Biotechnology for HIV Broadly Neutralising Antibody Functional Cure
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
December 2025
Gates Foundation Pledges $100 Million to Global Financing Facility for Women's and Children's Health 2026–2030
On December 6, 2025, at the Universal Health Coverage High-Level Forum in Tokyo, the Gates Foundation pledged $100 million to the World Bank-hosted Global Financing Facility's 2026–2030 strategy for ending preventable deaths among women, children, and adolescents in LMICs. The pledge brings the foundation's total GFF commitment past $500 million since 2015. The GFF provides catalytic grant financing and technical assistance to strengthen LMIC health systems and expand quality access to health and nutrition services for the world's most vulnerable populations.
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.